05.17.26 -- Three Radiopharma CEOs Talk Challenges And New Opportunities

This weekend’s selections from Life Science Leader share pro tips from industry executives navigating changes in the regulatory and technological landscape. In radiopharmaceuticals, new isotopes have emerged as the backbone of new therapeutics, and three CEOs joined a live panel to talk about new indication opportunities and operational challenges associated with delivering radiopharmaceuticals to patients.

On the regulatory front, experts Kimberly Chew and Odette Hauke explore the risks embedded in the FDA’s real-time clinical trial monitoring pilot. Modernizing the FDA is critical for maintaining the U.S.’s innovative edge, and real-time trial monitoring could speed up regulatory decision-making. However, speed is not the only measure of success, write Chew and Hauke.

On the Business of Biotech, Infinimmune’s Wyatt McDonnell, Ph.D. explains how computation and next-generation sequencing technology evolved to jumpstart the discovery of human-derived antibody drugs.

Check out a curated selection from our partners, below, and thanks as always for reading.

Ben Comer         
Chief Editor, Life Science Leader

Cencora highlights how regulatory complexity and fragile logistics create technology and operational issues that can derail CGT delivery and patient outcomes.

Ergomed Clinical Research shows how expert regulatory strategy and adaptive technologies help oncology teams overcome design complexity and accelerate trials responsibly.

EmVenio Clinical Research illustrates how mobile research nurses use flexible technology and regulatory-ready practices to overcome access barriers and bring trials to patients.

Flourish Research shows how advanced site strategies help teams overcome regulatory and operational obstacles to accelerate complex oncology enrollment without sacrificing quality.

SK pharmteco explains how specialized payload and linker expertise helps developers clear technical and regulatory barriers in increasingly complex ADC programs.

Citeline explores how data, AI, and trust-building strategies help sponsors overcome recruitment impediments in a rapidly expanding rare disease trial landscape.

AutoCruitment breaks down how digital recruitment technologies help sponsors jump enrollment hurdles and avoid costly delays in modern clinical trials.